<a href="https://www.fiercebiotech.com/biotech/viridians-tepezza-rival-racks-second-phase-3-win-clearing-path-fda" hreflang="en">Viridian’s Tepezza rival racks up second phase 3 win, clearing path to FDA</a>
Viridian Therapeutics' anti-IGF-1R antibody, elegrobart, has successfully completed its second phase 3 trial for treating thyroid eye disease (TED), meeting its primary endpoint and paving the way for FDA approval next year, positioning it as a competitor to Amgen's Tepezza. The trial results show significant improvements in proptosis reduction, indicating potential market competition, although Amgen's data suggests it may still have an efficacy advantage.
Viridian Therapeutics' recent success in their phase 3 trials for elegrobart, a subcutaneous anti-IGF-1R antibody, positions them to challenge Amgen's Tepezza in the thyroid eye disease market. With FDA filing planned for next year, the drug's convenience as a less frequent self-administered injection could offer a competitive advantage over Tepezza's infusion regimen, despite Amgen's potential efficacy edge and upcoming subcutaneous version. This development could signal a significant shift in the TED market dynamics, and may present an investment opportunity in Viridian as they expand their market presence.